ClinicalTrials.gg
TerminatedNCT04226365PeConUpdated Sep 10, 2025Results posted

Pediatric Concussion Outcomes

A Phase 4 interventional study of Nortriptyline and Placebo in Concussion Post Syndrome, Headaches Posttraumatic and Mild Traumatic Brain Injury, sponsored by Lancaster General Hospital. Terminated at 1 site in United States. Open to participants aged 13 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Lancaster General Hospital · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
The study was stopped prematurely due to a low enrollment rate.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
13 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Post-Concussion Syndrome with a site in United States — 15 open to participants now, 20 under way, 1 of them phase 3. Post-Concussion Syndrome · United States.

Enrollment
54th of 61
8 · median 40
Started
2020
with 3 others
Phase 4
2 of 77
1 open now
Registered
46th of 77
by date

Among the 77 studies in Post-Concussion Syndrome with a site in United States, this one is the 54th largest by enrollment of the 61 interventional ones that give a count, is one of 4 that started in 2020, is one of 2 in phase 4, and was the 46th registered.

Post-Concussion Syndrome

140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.

Browse Post-Concussion Syndrome studies →

Open to participants now

15 of the 77 studies in Post-Concussion Syndrome with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Post-Concussion Syndrome studies recruiting now, 3 (13%) set no upper age limit and 20 (83%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 13 Years to 21 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Post-Concussion Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, placebo-controlled, double-blinded trial in which subjects with a post concussive headache meeting inclusion criterion will be assigned to one of two treatment groups: placebo or nortriptyline. Each group will be evaluated at week 0 and again each week for the next 4 weeks of treatment with a concussion survey that rates their symptoms. At the end of 4 weeks the study will be unblinded. It is hypothesized that the addition of nortriptyline to the standard headache treatments will result in more rapid decrease of symptom score than with placebo.

Read the detailed description

Participants are randomly assigned to one of two treatment groups. The experimental group receives standard headache treatment including Tylenol, NSAIDs 2-3x/week, vestibular PT and daily nortriptyline 10mg oral. The control group also receives the standard headache treatment, but will instead be given a placebo, which will look physically identical to the nortriptyline capsule and be comprised of non-active pharmaceutical grade excipient.

03

Conditions studied

  • Concussion Post Syndrome
  • Headaches Posttraumatic
  • Mild Traumatic Brain Injury

Keywords

  • concussion
  • headache
  • mild TBI
  • post concussion
04

Who can participate

Ages eligible
13 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Participants aged 13-21 years old
  4. In good general health as evidenced by medical history and diagnosed with recent head trauma meeting ICHD-3 criteria for acute posttraumatic headache with symptom onset \< 7 days from trauma
  5. Ability to take oral medication and be willing to adhere to the medication regimen
  6. No loss of consciousness OR loss of consciousness \<30 minutes
  7. Headache symptoms persisting ≥4 weeks post trauma
  8. PCSHE score for headache + pressure in head + neck pain must be > 3
  9. After week 4 post-concussion at time of enrollment
  10. Not currently receiving pharmacologic treatment for concussion asid from NSAIDs and acetaminophen

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Focal neurological deficits following injury
  2. Any acute abnormality on Computed Tomography (if obtained)
  3. History of known seizure disorder or moderate or severe TBI
  4. Current uncontrolled psychiatric illness given the potential side effects of the study drug (at investigator discretion).
  5. Current suicidal ideation as screened for on PHQ on intake
  6. A personal history of Brugada syndrome
  7. Known allergic reaction to nortriptyline
  8. Current pregnancy
  9. Positive COVID-19 test in prior 14 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Experimental

    10mg capsule once daily for 4 weeks of nortriptyline

    Drug: Nortriptyline

  • Placebo comparator
    Control

    10mg capsule once daily for 4 weeks of Thick-It filler

    Drug: Placebo

Interventions

  • 10mg capsule Nortryptyline

    Also known as: Pamelor

  • DrugPlacebo

    10mg capsule Thick-It filler

06

What researchers measure

Primary outcomes

  1. Post-Concussive Symptom Inventory (PSCI) Score

    Post-Concussive Symptom Inventory (PSCI) score of 0-1 on the headache symptom, where the score ranges from 0 (absent) to 6 (severe). A score of 0 is optimal, while a score of 6 is not optimal.

    Time frame: 4 weeks

07

Results

Posted Sep 10, 2025

Participant flow

Participant flow — Overall Study
MilestoneExperimentalControl
Started44
Completed44
Not completed00

Outcome measures

PrimaryPost-Concussive Symptom Inventory (PSCI) Score

Post-Concussive Symptom Inventory (PSCI) score of 0-1 on the headache symptom, where the score ranges from 0 (absent) to 6 (severe). A score of 0 is optimal, while a score of 6 is not optimal.

Time frame:
4 weeks

No measurements were reported for this outcome.

Adverse events

Collected over 39 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental0/4 (0%)0/4 (0%)2/4 (50%)
Control0/4 (0%)0/4 (0%)1/4 (25%)
Most frequent other events
Most frequent other events
EventExperimentalControl
Headache/MigraineNervous system disorders1/41/4
Sever's ApophysitisMusculoskeletal and connective tissue disorders1/40/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ExperimentalControlTotal
<=18 years448
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)ExperimentalControlTotal
Mean14.5 ± 214.7 ± 114.6 ± 2
Sex: Female, Male
Sex: Female, Male(Participants)ExperimentalControlTotal
Female224
Male224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ExperimentalControlTotal
Hispanic or Latino011
Not Hispanic or Latino437
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ExperimentalControlTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White437
More than one race011
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)ExperimentalControlTotal
United States448
08

Study locations

1 site
  • Penn Medicine Lancaster General Health
    Lancaster, Pennsylvania 17602, United States
09

References and documents

Publications

  • Choe MC, Blume HK. Pediatric Posttraumatic Headache: A Review. J Child Neurol. 2016 Jan;31(1):76-85. doi: 10.1177/0883073814568152. Epub 2015 Feb 10. PubMed 25670632 ↗
  • Kacperski J, Hung R, Blume HK. Pediatric Posttraumatic Headache. Semin Pediatr Neurol. 2016 Feb;23(1):27-34. doi: 10.1016/j.spen.2015.08.005. Epub 2015 Aug 19. PubMed 27017019 ↗
  • McCrory P, Meeuwisse W, Dvorak J, Aubry M, Bailes J, Broglio S, Cantu RC, Cassidy D, Echemendia RJ, Castellani RJ, Davis GA, Ellenbogen R, Emery C, Engebretsen L, Feddermann-Demont N, Giza CC, Guskiewicz KM, Herring S, Iverson GL, Johnston KM, Kissick J, Kutcher J, Leddy JJ, Maddocks D, Makdissi M, Manley GT, McCrea M, Meehan WP, Nagahiro S, Patricios J, Putukian M, Schneider KJ, Sills A, Tator CH, Turner M, Vos PE. Consensus statement on concussion in sport-the 5th international conference on concussion in sport held in Berlin, October 2016. Br J Sports Med. 2017 Jun;51(11):838-847. doi: 10.1136/bjsports-2017-097699. Epub 2017 Apr 26. No abstract available. PubMed 28446457 ↗
  • Makdissi M, Schneider KJ, Feddermann-Demont N, Guskiewicz KM, Hinds S, Leddy JJ, McCrea M, Turner M, Johnston KM. Approach to investigation and treatment of persistent symptoms following sport-related concussion: a systematic review. Br J Sports Med. 2017 Jun;51(12):958-968. doi: 10.1136/bjsports-2016-097470. Epub 2017 May 8. PubMed 28483928 ↗
  • Bernard CO, Ponsford JL, McKinlay A, McKenzie D, Krieser D. Do Concussive Symptoms Really Resolve in Young Children? J Head Trauma Rehabil. 2017 Nov/Dec;32(6):413-424. doi: 10.1097/HTR.0000000000000298. PubMed 28422893 ↗
  • Kuczynski A, Crawford S, Bodell L, Dewey D, Barlow KM. Characteristics of post-traumatic headaches in children following mild traumatic brain injury and their response to treatment: a prospective cohort. Dev Med Child Neurol. 2013 Jul;55(7):636-41. doi: 10.1111/dmcn.12152. Epub 2013 Apr 5. PubMed 23560811 ↗
  • Johnson JG, Harris ES, Spitzer RL, Williams JB. The patient health questionnaire for adolescents: validation of an instrument for the assessment of mental disorders among adolescent primary care patients. J Adolesc Health. 2002 Mar;30(3):196-204. doi: 10.1016/s1054-139x(01)00333-0. PubMed 11869927 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in May 2023, 39 months.

Results were first posted in Sep 2025, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2020
First posted
Jan 13, 2020
StartActual
Feb 15, 2020
Primary completionActual
May 31, 2023
CompletionActual
May 31, 2023
Results first posted
Sep 10, 2025
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04226365
Lead sponsor
Lancaster General Hospital
Responsible party
Sponsor
First posted
Jan 13, 2020
Start date
Feb 15, 2020
Primary completion
May 31, 2023
Completion
May 31, 2023
Results posted
Sep 10, 2025
Last update
Sep 10, 2025

Study contacts

Patrick Moreno, MD
principal investigator · Lancaster General Health Sports Medicine
Laura DiPaolo, MD
principal investigator · Lancaster General Health Sports Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nortriptyline

Start the discussion